{"analyses":[{"ciLowerLimit":"0.498","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.782","groupDescription":"Hazard ratio for OS and 95% confidence interval was calculated for stratified IVRS by using Cox model, stratified by the geographic region: Asia or Rest of the World (ROW), ECOG-PS: 0 versus 1, AFP level, presence versus absence of extrahepatic disease and presence versus absence of macrovascular invasion. Kaplan-Meier (KM) estimated for OS and KM survival curves were presented for each treatment arm.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"= 0.000017","paramType":"Hazard Ratio (HR)","paramValue":"0.624","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.527","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.828","groupDescription":"Hazard ratio for OS and 95% confidence interval was calculated for stratified RAVE (Sensitivity) by using Cox model, stratified by the geographic region: Asia or Rest of the World (ROW), ECOG-PS: 0 versus 1, AFP level, presence versus absence of extrahepatic disease and presence versus absence of macrovascular invasion. Kaplan-Meier (KM) estimated for OS and KM survival curves were presented for each treatment arm.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"= 0.000149","paramType":"Hazard Ratio (HR)","paramValue":"0.660","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.546","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.831","groupDescription":"Hazard ratio for OS and 95% confidence interval was calculated for unstratified (sensitivity) by using Cox model, stratified by the geographic region: Asia or Rest of the World (ROW), ECOG-PS: 0 versus 1, AFP level, presence versus absence of extrahepatic disease and presence versus absence of macrovascular invasion. Kaplan-Meier (KM) estimated for OS and KM survival curves were presented for each treatment arm.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"= 0.000107","paramType":"Hazard Ratio (HR)","paramValue":"0.674","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"192","spread":"192","upperLimit":"269","value":"237"},{"groupId":"OG001","lowerLimit":"276","spread":"276","upperLimit":"369","value":"323"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"379"}],"units":"Participants"}],"description":"Overall Survival (OS) was defined as the time from date of randomization (Day 1) to death due to any cause. Subjects still alive at the time of analysis were censored at their last date of last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"Subjects received placebo matched to regorafenib coated tablets orally every day for 3 weeks followed by 1 week off treatment plus best best supportive care.","id":"OG000","title":"Placebo"},{"description":"Subjects received regorafenib 160 milligram (mg) (4 \\* 40 mg coated tablets) orally every day for 3 weeks followed by 1 week off treatment plus BSC.","id":"OG001","title":"Regorafenib 160 mg (BAY73-4506)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From randomization (Day 1) of the first subject until 419 days later","title":"Overall Survival (OS)","type":"PRIMARY","unitOfMeasure":"days"}